Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 1 of 1
Full-Text Articles in Medicine and Health Sciences
Randomized, Double-Blind, Phase Ii Study Of Temozolomide In Combination With Either Veliparib Or Placebo In Patients With Relapsed-Sensitive Or Refractory Small-Cell Lung Cancer, M Catherine Pietanza, Saiama N Waqar, Et Al
Randomized, Double-Blind, Phase Ii Study Of Temozolomide In Combination With Either Veliparib Or Placebo In Patients With Relapsed-Sensitive Or Refractory Small-Cell Lung Cancer, M Catherine Pietanza, Saiama N Waqar, Et Al
2010-2019 OA Pubs
Purpose Both temozolomide (TMZ) and poly (ADP-ribose) polymerase (PARP) inhibitors are active in small-cell lung cancer (SCLC). This phase II, randomized, double-blind study evaluated whether addition of the PARP inhibitor veliparib to TMZ improves 4-month progression-free survival (PFS). Patients and Methods A total of 104 patients with recurrent SCLC were randomly assigned 1:1 to oral veliparib or placebo 40 mg twice daily, days 1 to 7, and oral TMZ 150 to 200 mg/m